If TRPV1 represents a bottleneck pathway in bladder pathologies associated with NGF up-regulation, TRPV1 antagonists may demonstrate therapeutic relevance in BPS/IC patients as well. The gene discussed is NGF; the disease is Bartsocas-Papas syndrome 1.